PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: AnaSpec, Inc.

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

AnaSpec Introduces New Line of Secretase Research Solutions - As scientific research explores the role of b-Amyloid in Alzheimer’s Disease, the secretases whose cleavage activity produces b-Amyloid fragments have become an important focus.
AnaSpec Introduces New Line of Secretase Research Solutions

 

NewswireToday - /newswire/ - San Jose, CA, United States, 2006/08/02 - As scientific research explores the role of b-Amyloid in Alzheimer’s Disease, the secretases whose cleavage activity produces b-Amyloid fragments have become an important focus..

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Amyloid Precursor Protein, APP, a transmembrane glycoprotein of about 770 amino acids, is cleaved by a-Secretase and b-Secretase to produce C-terminal fragments that are 83 amino acids (C83) and 99-amino acids (C99) in length, respectively. Subsequent cleavages of C83 and C99 by g-Secretase produce a 3-kD (p3) protein in the former and a 4-kD (b-amyloid) protein in the latter and a CT57-59 in both fragments (reviewed in 1, 2). The 4-Kd consists of Ab which are 39 to 42 amino acids in length, with Ab 1-42 being the major component of amyloid plaques which accumulates in neurons of Alzheimer’s disease (AD) brain. Consequently, b-Secretase is an important target for AD drug development.

FRET Secretase Substrates

AnaSpec provides fluorescence resonance energy transfer (FRET) substrates for use in measuring b-Secretase activity. Upon cleavage of the FRET substrate by b-Secretase, the quenched fluorescence of the donor is released, with the fluorescence signal increasing with b-Secretase activity. Variations include a range of sequence lengths and emission wavelengths.

· Wild-Type
· Swedish Double Mutation (K670N/M671L)

EnzoLyte™ 520 ß-Secretase Assay Kit
· Ready-to-use assay kit for detection of b-Secretase V. 100 assays.

b -Secretase inhibitors
· High-purity peptides that inhibit b-Secretase activity.

a -Secretase Substrate
· A FRET-based a-Secretase substrate, which upon cleavage liberates the Mca (7-Methoxycoumarin-4-acetic acid) fragment from the proximity quenching effect of Dnp (2,4-dinitrophenyl), Abs/Em=325/393 nm.

References:
1. Selkoe DJ. Nature 399, A23 (1999).
2. Suh, Y-H. and F. Checler. Pharma. Rev. 54, 469 (2002).

For more information, visit our website.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: AnaSpec, Inc.

 
 

Availability: All Metropolitan Area

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


AnaSpec Introduces New Line of Secretase Research Solutions

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Debra Thai 
408-452-5055 marketing[.]anaspec.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any AnaSpec, Inc. securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From AnaSpec, Inc. / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

U.S. FDA Approves New Indication for Ipsen’s Somatuline® Depot (lanreotide) Injection for the Treatment of Carcinoid Syndrome
Genentech Provides Update on First Lampalizumab Phase III Study for Geographic Atrophy, an Advanced Form of Age-Related Macular Degeneration
mProve Health and Greenphire Partner to Deliver a First-of-its-Kind Patient Engagement Solution
FDA Approves Genentech’s Actemra (Tocilizumab) for the Treatment of CAR T Cell-Induced Cytokine Release Syndrome
Greenphire Named to Inc. 5000 for Fifth Consecutive Year
Five Community Health Centers Honored for Innovative Approaches to Medication Therapy Management
FDA Grants Priority Review for Genentech’s Gazyva in Previously Untreated Follicular Lymphoma
ProSci Incorporates Flow Cytometry Screening to Custom Monoclonal Antibody Service
FDA Grants Priority Review to Genentech's Emicizumab for Hemophilia A with Inhibitors
BD Expands Suite of Blood Culture Offerings with New BD BACTEC™ Standard Aerobic & Standard Anaerobic Plastic Bottles
Twist Bioscience Collaborates with Synbio Technologies to Supply Long DNA to Customers
FDA Grants Priority Review and Breakthrough Therapy Designation for Zelboraf (vemurafenib) in Erdheim-Chester Disease with BRAF V600 Mutation
Ipsen Receives Positive CHMP Opinion for Approval of Xermelo® (telotristat Ethyl)
BD Receives FDA 510(k) Clearance for New Immunological Diagnostic System
Positive Phase III Results for Genentech’s Emicizumab in Hemophilia A Published in The New England Journal of Medicine

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  NAKIVO, Inc.

Visit  JobsWare.com





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)